一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
非小细胞肺癌中的肿瘤浸润 B 细胞：当前认识与未来方向
英文原题：Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.
查看英文原题
Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤浸润免疫细胞已被广泛认为在促进或抑制肿瘤生长中发挥重要作用。近年来，肿瘤微环境中的肿瘤浸润B细胞日益受到关注。然而，B细胞在非小细胞肺癌中的作用仍 largely 未知。通过回顾近期研究，我们在此描述了非小细胞肺癌中B淋巴细胞的分布、表型和异质性，展示了它们的功能，并讨论了不同B细胞亚型的预后意义以及针对TIL-B的潜在治疗策略。最后，本综述强调了未来研究进一步阐明其在肿瘤微环境中精确功能的必要性。
展开英文摘要原文
Tumor-infiltrating immune cells have been widely recognized as playing an important role in the promotion or inhibition of tumor growth. Recently there has been increasing attention on tumor-infiltrating B cells in the tumor microenvironment.
However, the role of B cells in non-small cell lung cancer remains largely unknown. Reviewing recent studies, here we describe the distribution, phenotype, and heterogeneity of B lymphocytes in the non-small cell lung cancer, present their functions and discuss the prognostic significance of the different B-cell subtypes as well as potential therapeutic strategies targeting TIL-Bs.
Finally, the review highlights the need for future research to further elucidate their precise function in the tumor microenvironment.
论文信息
- 作者
- Jiang S、Zhu D、Wang Y
- 第一作者单位
- Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.China
- 通讯作者单位
- Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. doctordream0630@163.com.China
- 文献类型
- 综述
- 期刊
- Cancer cell international2025 Feb 26
- 原文标识
- PubMed 40011889 · DOI 10.1186/s12935-025-03668-3
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →